FORTITUDE-101 Study Updates 2025: Bemarituzumab Plus mFOLFOX6 in FGFR2b-Positive Gastric and GEJ Cancer - OncoDaily FORTITUDE-101 Study shows that Bemarituzumab Plus mFOLFOX6 improves OS in patients with FGFR2b-Positive Gastric and GEJ Cancer.

FORTITUDE-101 Study Updates 2025: Bemarituzumab Plus mFOLFOX6 in FGFR2b-Positive Gastric and GEJ Cancer

oncodaily.com/oncolibrary/...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #FORTITUDE101 #Bemarituzumab #mFOLFOX6 #GEJCancer #GastricCancer

Maria (Masha) Babak: FDA grants accelerated approval to Braftovi for the treatment of metastatic colorectal cancer - OncoDaily Maria (Masha) Babak: FDA grants accelerated approval to Braftovi for the treatment of metastatic colorectal cancer / Braftovi, cancer, cetuximab, colorectal

FDA grants accelerated approval to Braftovi for the treatment of metastatic colorectal cancer - Maria (Masha) Babak
@thebabaklab.bsky.social
@fda.gov

oncodaily.com/blog/222646

#Braftovi #Cancer #Cetuximab #ColorectalCancer #FDA #Encorafenib #mCRC #mFOLFOX6 #OncoDaily #Oncology #Medicine #Health

FDA Grants Accelerated Approval to Encorafenib, Cetuximab, and mFOLFOX6 for BRAF V600E Metastatic Colorectal Cancer - OncoDaily FDA Grants Accelerated Approval to Encorafenib, Cetuximab, and mFOLFOX6 for BRAF V600E Metastatic Colorectal Cancer / BREAKWATER trial, cancer, cetuximab,

FDA Grants Accelerated Approval to Encorafenib, Cetuximab, and mFOLFOX6 for BRAF V600E Metastatic Colorectal Cancer
@fda.gov

oncodaily.com/insight/210177

#BREAKWATERtrial #Cancer #Cetuximab #ColorectalCancer #Encorafenib #FDA #mFOLFOX6 #OncoDaily #Oncology #Medicine #Health